Moderna, Inc. (MRNA) Q2 2025 Earnings Results

Moderna Misses on Revenue, Stock Down 6.61%

This earnings report indicates that while Moderna's EPS beat expectations, the lack of revenue details and the stock's decline of 6.61% suggest investor concerns. The management's defensive tone points to potential challenges in the market, which may affect future performance. Without guidance, uncertainty remains about the company's direction in the coming quarters.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-2.13	N/A	+28.60%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Overall, management conveyed a cautious outlook, emphasizing the challenges ahead. They did not provide specific guidance for the upcoming quarters.

Management expressed concerns about ongoing market conditions.

They highlighted the need for strategic adjustments moving forward.

Moderna Misses on Revenue, Stock Down 6.61%

Key numbers

Management commentary

Moderna, Inc.

More earnings this week

Moderna Misses on Revenue, Stock Down 6.61%

Key numbers

Management commentary